What’s On CEO Andrew Witty’s To-Do List Before Exiting GSK
This article was originally published in The Pink Sheet Daily
Executive Summary
The company showed signs of stabilization in the first quarter, as Witty insisted his diversified strategy is beginning to pay off. But a new CEO will have to contend with the potential entry of Advair generics.
You may also be interested in...
ViiV’s Visibility Grows And Pressure Mounts For What Comes Next
GlaxoSmithKline’s HIV-focused business unit is growing leaps and bounds, while the company’s other pharmaceutical sales slump. ViiV CEO Dominique Limet talked in an interview about the increased pressure success brings and how ViiV intends to keep delivering.
Witty Exiting GSK In 2017, Raising Questions About The Firm’s Future
GlaxoSmithKline CEO Andrew Witty will retire from the company in 2017 after nine years at the helm, opening the door to the possibility of broader change.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.